Viewing data from:

OPTIMARK

NDA

GADOVERSETAMIDE | N020937 | LIEBEL-FLARSHEIM CO LLC

4 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

12 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 1654.5MG/5ML (330.9MG/ML)

RLD

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Dec 8, 1999

No patent or exclusivity listings for this strength.

#002 — 3309MG/10ML (330.9MG/ML)

RLD

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Dec 8, 1999

#003 — 4963.5MG/15ML (330.9MG/ML)

RLD

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Dec 8, 1999

#004 — 6618MG/20ML (330.9MG/ML)

RLD

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Dec 8, 1999